经筋透刺法联合穴位注射治疗顽固性面瘫 60例临床观察

目的 探讨经筋透刺法联合穴位注射治疗顽固性面瘫的临床疗效。方法 选取2020年5月至2021年10月在遂宁市中医院接受治疗的120例顽固性面瘫病人，采用随机数字表法随机分为单一组（60例）和联合组（60例），两组病人均给予常规西药治疗，单一组在此基础上给予穴位注射，联合组在此基础上给予经筋透刺法联合穴位注射，比较两组病人治疗前后面神经功能、神经生长因子（NGF）和胶质细胞源性神经营养因子（GDNF）水平、神经功能分级（H-B）评分、面瘫Portmann评分、Sunnybrook量表、复发率及临床疗效。结果 单一组和联合组治疗后面神经功能明显改善，且联合组面神经功能改善情况明显优于单一组（P<0.05）；单一组H-B评分治疗后较治疗前降低（2.63±0.54）分比（4.01±0.73）分，联合组（1.67±0.49）分比（4.03±0.71）分（P<0.05），且联合组H-B评分低于单一组（P<0.05），单一组和联合组GDNF(12.16±3.33)mg/L比（8.92±1.35）mg/L、（15.54±3.42）mg/L比（8.89±1.37）mg/L、NGF水平（...

Clinical observation on the treatment of 60 cases of refractory facial paralysis by meridian tendon penetration and stabbing method combined with acupoint injection

Objective To investigate the clinical efficacy of the meridian tendon penetration method combined with acupoint injec-tion in the treatment of refractory facial paralysis.Methods From May 2020 to October 2021, 120 patients with refractory facial paral-ysis who received treatment at Suining Hospital of Traditional Chinese Medicine were selected and randomly divided into a singlegroup (60 cases) and a combined group (60 cases) by using a random number table method. Both groups of patients were treated withconventional Western medicines, and the single group was given acupoint injections on this basis, while the combined group was giventhe meridian tendon penetration method combined with acupoint injection on this basis. The nerve function, nerve growth factor (NGF)and glial cell-derived neurotrophic factor (GDNF) levels, neurological function classification (H-B) scores, Portmann score of facial pa-ralysis, Sunnybrook scale, recurrence rate and clinical efficacy were compared between the two groups before and after treatment.Re- sults The facial nerve function in the single group and the combined group was significantly improved after treatment, and the im-provement in facial nerve function in the combined group was significantly better than that in the single group (P < 0.05). The H-B scores were lower after treatment than before treatment in the single group (2.63±0.54) points vs. (4.01±0.73) points], and in the com- bined group (1.67±0.49) points vs. (4.03±0.71) points] (P < 0.05), and the H-B scores in the combined group were lower than those in the single group (P < 0.05). Single group and combined group GDNF (12.16 ± 3.33) vs. (8.92 ± 1.35) mg/L, (15.54 ± 3.42) vs. (8.89 ± 1.37) mg/L], NGF levels (12.16 ± 3.33) vs. (8.92 ± 1.35) mg/L (15.54 ± 3.42) vs. (8.89 ± 1.37) mg/L], facial paralysis Portmann score (15.31 ± 1.03) vs. (6.69 ± 0.68) points, (17.24 ± 1.16) vs. (6.72 ± 0.71) points], Sunnybrook scale score (69.16 ± 10.67) vs. (36.42 ± 10.17)points, (78.64 ± 11.56) vs. (36.17 ± 10.13)points] increased after treatment compared to before treatment, and levels of GDNFand NGF, facial paralysis Portmann score, and Sunnybrook scale score in the combined group were higher than those in the singlegroup (P < 0.05). The total recurrence rate of the combined group (3.33%) was lower than that of the single group (13.33%) (P < 0.05)